Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Nature
|
May 22, 2009
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Kwan-Hyuck Baek, Alexander Zaslavsky, Ryan C Lynch, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
Jason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
Eclinicalmedicine
|
September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
Marek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
JCO Oncology Practice
|
May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy
Mary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
British Journal of Haematology
|
February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia
Chaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma
Mark Roschewski, David M Kurtz, Jason R Westin, et al.
Blood Advances
|
December 15, 2022
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
Ryan C Lynch, Christina Poh, Chaitra S Ujjani, et al.
Nature
|
May 28, 2025
Domesticated cannabinoid synthases amid a wild mosaic cannabis pangenome
Ryan C Lynch, Lillian K Padgitt-Cobb, Andrea R Garfinkel, et al.
Future Oncology (London, England)
|
July 6, 2026
Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
The Lancet. Haematology
|
July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Nature
|
May 22, 2009
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Kwan-Hyuck Baek, Alexander Zaslavsky, Ryan C Lynch, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
Jason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.
Eclinicalmedicine
|
September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
Marek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
JCO Oncology Practice
|
May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy
Mary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
British Journal of Haematology
|
February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia
Chaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma
Mark Roschewski, David M Kurtz, Jason R Westin, et al.
Blood Advances
|
December 15, 2022
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
Ryan C Lynch, Christina Poh, Chaitra S Ujjani, et al.
Nature
|
May 28, 2025
Domesticated cannabinoid synthases amid a wild mosaic cannabis pangenome
Ryan C Lynch, Lillian K Padgitt-Cobb, Andrea R Garfinkel, et al.
Future Oncology (London, England)
|
July 6, 2026
Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
The Lancet. Haematology
|
July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Page
of 8